Maria Babak: Clear and comprehensive breakdown of the cancer staging process using the TNM system
shared a post by on LinkedIn, adding: .
“Check out a clear and comprehensive breakdown of the cancer staging process using the TNM system. By understanding this system patients and their families can better grasp what each stage means. Additionally, the post highlights the exciting advancements in genetic testing and treatments that are improving outcomes and offering new hope.
If you or someone you know is navigating a cancer diagnosis, this carousel is a must-see for valuable insights and encouragement.“
Quoting the post by
“Understanding Cancer Staging and the TNM System.
Navigating a cancer diagnosis can be overwhelming and confusing, especially when trying to understand what the stage number means. To help demystify this process, we’ve created a carousel that breaks down how doctors determine cancer stages using the TNM system.
Explore the carousel to learn more about what each stage represents and how advances in treatment and genetic testing are continually refining cancer staging. These medical advancements are improving patient outcomes and providing hope for a brighter future.
We hope this information helps you or your loved ones better understand cancer staging and the strides being made in cancer treatment. Together, we can face this challenge with knowledge, strength, and optimism.”
Source:
Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. She earned her Ph.D. in bioinorganic chemistry from the University of Vienna in 2014. From 2015 to 2020, Dr. Babak was a postdoctoral research fellow at the National University of Singapore under the mentorship of Prof.
Wee Han Ang, where she developed a strong passion for drug discovery and drug target identification. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.
Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.
